Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 2 of 4: Calculated dose-response metrics. - Dataset (ID:20269)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Biological Replicate ID | Conc Unit | GR50 | GEC50 | GRmax | GRinf | GR Hill Coefficient | GR_AOC | GR r2 | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 184A1 | NM | Basal | Temsirolimus | MTOR | MTOR | 12509.168 | uM | 0.69862 | 4.34640 | -0.9247 | -1.0000 | 0.6010 | 0.6200 | 0.8824 | 1.3516 | |
| 184A1 | NM | Basal | Topotecan | TOP1 | TOP | 9047.121 | uM | 0.06571 | 0.20129 | -0.5195 | -0.5794 | 0.6874 | 0.8137 | 0.9412 | 0.7949 | |
| 184A1 | NM | Basal | Docetaxel | TUBB | TUBB | 9047.002 | uM | 0.00721 | 0.00164 | 0.3271 | 0.2689 | 0.5211 | 0.4844 | 0.7111 | 0.5243 | |
| 184A1 | NM | Basal | GW-5074 | CRAF | MAPK | 5895.088 | uM | 2.20640 | 4.30790 | -0.5359 | -0.6571 | 1.2540 | 0.2508 | 0.9932 | 1.3297 | |
| 184A1 | NM | Basal | Tozasertib | AURK/FLT3/ABL/JAK2 | AURK | 12509.169 | uM | 2.47570 | 23.78060 | -0.3199 | -1.0000 | 0.4856 | 0.3696 | 0.9823 | 1.5064 | |
| 184A1 | NM | Basal | TPCA-1 | IKK | NFKB | 5895.093 | uM | 4.52640 | 2.6040 | 0.3659 | 0.3912 | 2.7579 | 0.1290 | 0.9836 | 1.3259 | |
| 184A1 | NM | Basal | Ibandronate | FDPS | 12509.143 | uM | 155.22840 | 288.34070 | -0.9140 | -1.0000 | 1.7741 | 0.2785 | 0.9964 | 1.3392 | ||
| 184A1 | NM | Basal | Trametinib | MEK | MAPK | 9047.012 | uM | 0.00121 | 0.00198 | -0.2658 | -0.2622 | 0.8548 | 0.8904 | 0.9728 | 0.7549 | |
| 184A1 | NM | Basal | Trametinib | MEK | MAPK | 10002.012 | uM | 0.00246 | 0.00373 | -0.3319 | -0.3425 | 1.2572 | 0.8816 | 0.9950 | 0.5807 | |
| 184A1 | NM | Basal | Docetaxel | TUBB | TUBB | 10002.002 | uM | inf | 0.00813 | 0.5141 | 0.5151 | 1.4431 | 0.2780 | 0.7979 | 0.9502 | |
| 184A1 | NM | Basal | ICRF-193 | TOP2 | TOP | 12509.157 | uM | inf | 0.17119 | 0.6433 | 0.6783 | 0.6598 | 0.1328 | 0.9202 | 1.2837 | |
| 184A1 | NM | Basal | Trastuzumab | HER2 | ErbB | 9047.026 | uM | inf | inf | 0.2837 | 0.2837 | 0.0000 | 0.2170 | 0.0804 | 0.5972 | |
| 184A1 | NM | Basal | Carboplatin | DNA cross-linker | DNA cross-linker | 9047.011 | uM | 9.5630 | 14.41690 | -0.9873 | -0.8900 | 2.4907 | 0.7356 | 0.9439 | 0.6293 | |
| 184A1 | NM | Basal | Trichostatin A | HDAC | HDAC | 5895.065 | uM | 18.79790 | 50.3060 | -0.9456 | -0.9673 | 1.0936 | 0.6799 | 0.9969 | 1.3748 | |
| 184A1 | NM | Basal | IKK16 | IKK | NFKB | 5895.093 | uM | 1.01110 | 2.37210 | -0.9564 | -1.0000 | 1.2884 | 0.5085 | 0.9882 | 1.3259 | |
| 184A1 | NM | Basal | Trichostatin A | HDAC | HDAC | 5894.065 | uM | 21.390 | 58.12760 | -0.8469 | -0.8364 | 0.9834 | 0.6280 | 0.9974 | 1.6064 | |
| 184A1 | NM | Basal | Triciribine | AKT | AKT | 5894.074 | uM | 0.10268 | 0.28489 | -0.6622 | -0.6112 | 0.7825 | 0.5807 | 0.9866 | 1.4541 | |
| 184A1 | NM | Basal | Docetaxel | TUBB | TUBB | 12684.002 | uM | inf | 0.00450 | 0.5376 | 0.5289 | 1.1663 | 0.2796 | 0.9570 | 1.5245 | |
| 184A1 | NM | Basal | Imatinib | ABL/KIT/PDGFR | nRTK | 5895.091 | uM | 16.09010 | 26.49230 | -0.9899 | -1.0000 | 2.2032 | 0.4630 | 0.9969 | 1.1729 | |
| 184A1 | NM | Basal | Triciribine | AKT | AKT | 5895.074 | uM | 0.08792 | 0.23992 | -0.7686 | -0.7129 | 0.8827 | 0.6419 | 0.9956 | 1.1218 | |
| 184A1 | NM | Basal | Valproic acid | HDAC | HDAC | 12509.143 | uM | 612.3160 | 1000.00000 | -0.4448 | -0.3207 | 1.0103 | 0.2717 | 0.9441 | 1.3392 | |
| 184A1 | NM | Basal | Ispinesib | KSP | Kinesin | 5894.067 | uM | 1.62180 | 3.48940 | -0.9288 | -1.0000 | 1.4339 | 0.3983 | 0.9581 | 1.5647 | |
| 184A1 | NM | Basal | Vinorelbine | TUBB | TUBB | 7787.018 | uM | inf | inf | -0.9963 | -0.9963 | 0.0000 | 0.4831 | 0.4499 | 0.3791 |